As regards JAK inhibitors, Sparks et al (2021)27 documented that when compared to RA patients who used anti‐TNF therapies, RA patients who received rituximab or JAK inhibitors at the time of COVID‐19 infection were more likely to have poor COVID‐19 outcomes that ranged from hospitalization to death. Here, TNF is linked to COVID-19.